Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | MMP1 | P03956 | 2/20 | 0.56 |
| ▸ | FCER2 | P06734 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
| ▸ | KLK7 | P49862 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 2/20 | 0.51 |
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | METAP1 | P53582 | 1/20 | 0.51 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5520883 | 0.88 | MAPT (0.54) | RAB9ANPC1MMP1FCER2EPHX1 | |
| SCHEMBL5520634 | 0.87 | CTSK (0.60) | RAB9ANPC1MMP1FCER2HPGD | |
| SCHEMBL4715141 | 0.86 | EPHX2 (0.63) | RAB9ANPC1MMP1EPHX1SMN1; SMN2 | |
| SCHEMBL5521787 | 0.86 | PKM (0.53) | HPGDALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL5520558 | 0.84 | CPB2 (0.62) | RAB9ANPC1HPGDKLKB1ALDH1A1 | |
| SCHEMBL5523633 | 0.84 | EPHX1 (0.57) | MMP1EPHX1MMP8KMT2AEPHX2 | |
| SCHEMBL5534127 | 0.83 | CHRNB2 (0.50) | RAB9ANPC1EPHX1METAP2METAP1 | |
| SCHEMBL5528540 | 0.83 | EPHX1 (0.58) | RAB9ANPC1MMP1FCER2EPHX1 | |
| SCHEMBL5671350 | 0.81 | CTSL (0.48) | RAB9ANPC1MMP1FCER2HPGD | |
| SCHEMBL19272538 | 0.80 | NPC1 (0.54) | RAB9ANPC1MMP1FCER2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1399146-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARM INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | AXYS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| EP-1399146-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002098406-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | RAB9A 512/4885NPC1 37/4885MMP1 359/4885 |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | CAPNS1, CTSS, CTSV | RAB9A 2178/4885NPC1 1596/4885MMP1 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.